Analyst Reco. Twist Bioscience Corporation

Equities

TWST

US90184D1000

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
31.54 ^USD	+1.48%		+12.84%	-14.43%

03-28	Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations	CI
03-12	Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating	02-05	MT
Barclays Raises Price Target on Twist Bioscience to $45 From $30, Keeps Overweight Rating	01-25	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Raises Price Target to $45 From $25	01-18	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Price Target is $45	01-17	MT
Evercore ISI Raises Twist Bioscience Price Target to $32 From $26, Maintains Outperform Rating	11-17	MT
Berenberg Initiates Coverage on Twist Bioscience with Buy Rating, $27 Price Target	23-09-27	MT
Barclays Adjusts Price Target on Twist Bioscience to $26 From $20, Keeps Overweight Rating	23-08-07	MT
Barclays Adjusts Twist Bioscience Price Target to $26 From $20, Maintains Overweight Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $18, Maintains Neutral Rating	23-07-13	MT
Barclays Adjusts Price Target on Twist Bioscience to $20 From $32, Maintains Overweight Rating	23-05-08	MT
Baird Adjusts Twist Bioscience Price Target to $18 From $29, Maintains Outperform Rating	23-05-08	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $43, Maintains Neutral Rating	23-04-18	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $43 From $50, Maintains Neutral Rating	23-02-06	MT
Barclays Adjusts Price Target on Twist Bioscience to $32 From $37, Maintains Overweight Rating	23-02-06	MT
Baird Adjusts Price Target on Twist Bioscience to $29 From $33, Maintains Outperform Rating	23-02-06	MT
Barclays Adjusts Price Target on Twist Bioscience to $37 From $43, Maintains Overweight Rating	23-01-30	MT
Scotiabank Initiates Twist Bioscience at Outperform Rating With $33 Price Target	23-01-05	MT
Scotiabank Initiates Twist Bioscience at Sector Outperform With $33 Price Target	23-01-05	MT
Evercore ISI Upgrades Twist Bioscience to Outperform From In Line, Adjusts Price Target to $36 From $28	23-01-03	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $30 From $45, Keeps Market Perform Rating	22-11-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Twist Bioscience Corporation

Equities

TWST

US90184D1000

Analyst Reco.

Filters